secwatch.observer — SEC 8-K summary
======================================

Issuer:     INCYTE CORP (INCY)
CIK:        0000879169
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0000879169-26-000016
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incyte appoints Cagnoni as President, integrates U.S. commercial; Trotta departs
--------------------------------------------------------------------------------

- Pablo Cagnoni named President, Incyte and Global Head of R&D; replaces Bill Meury as President; Meury remains CEO.
- Steven Stein promoted to EVP, Chief Medical Officer and Head of Late-stage Development.
- Mohamed Issa becomes EVP and Head of U.S. Commercial; U.S. oncology and immunology teams integrated.
- Matteo Trotta, EVP and GM of U.S. Dermatology, will leave Incyte after a transition period.
- No changes to compensation for the impacted executives in connection with these title changes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879169/000087916926000016/0000879169-26-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879169/000087916926000016/incy-20260325.htm
  HTML page:      https://secwatch.observer/filing/0000879169-26-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer